NASDAQ:SNTS - Santarus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Santarus (NASDAQ:SNTS)

Santarus logoSantarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Receive SNTS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Santarus (NASDAQ:SNTS) Frequently Asked Questions

What is Santarus' stock symbol?

Santarus trades on the NASDAQ under the ticker symbol "SNTS."

Has Santarus been receiving favorable news coverage?

Headlines about SNTS stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Santarus earned a news impact score of 0.24 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Santarus?

Shares of SNTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Santarus?

Santarus' mailing address is 3611 Valley Centre Dr Ste 400, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-3145700.

MarketBeat Community Rating for Santarus (SNTS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe SNTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNTS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Santarus (NASDAQ:SNTS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/22/2016 forward)


Santarus (NASDAQ:SNTS) Earnings History and Estimates Chart

Earnings by Quarter for Santarus (NASDAQ:SNTS)

Santarus (NASDAQ SNTS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2013Q313$0.33$0.45$94.45 million$98.79 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.18$0.94$82.90 million$89.40 millionViewN/AView Earnings Details
5/6/2013Q1 2013$0.15$0.25$74.70 million$79.44 millionViewN/AView Earnings Details
3/4/2013Q4 2012$0.01$0.08$62.02 million$70.20 millionViewN/AView Earnings Details
11/7/2012Q312$0.10$0.13$53.04 million$54.70 millionViewN/AView Earnings Details
8/7/2012$0.08$0.05ViewN/AView Earnings Details
5/8/2012($0.01)$0.01ViewN/AView Earnings Details
3/5/2012Q4 2011$0.02$0.03ViewN/AView Earnings Details
11/7/2011Q3 2011$0.01$0.01ViewN/AView Earnings Details
8/3/2011Q2 2011$0.04ViewN/AView Earnings Details
5/4/2011Q1 2011($0.03)($0.01)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.28)($0.03)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.21)($0.32)ViewN/AView Earnings Details
8/2/2010Q2 2010$0.04$0.10ViewN/AView Earnings Details
5/6/2010Q1 2010($0.01)$0.05ViewN/AView Earnings Details
3/3/2010Q4 2009$0.20$0.40ViewN/AView Earnings Details
11/4/2009Q3 2009($0.01)$0.09ViewN/AView Earnings Details
8/3/2009Q2 2009($0.01)$0.02ViewN/AView Earnings Details
5/6/2009Q1 2009($0.05)$0.02ViewN/AView Earnings Details
3/5/2009Q4 2008($0.01)$0.07ViewN/AView Earnings Details
11/3/2008Q3 2008($0.10)($0.08)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.05)$0.06ViewN/AView Earnings Details
5/7/2008Q1 2008($0.16)($0.15)ViewN/AView Earnings Details
3/3/2008Q4 2007($0.26)($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Santarus (NASDAQ:SNTS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Santarus (NASDAQ SNTS) Insider Trading and Institutional Ownership History

Insider Trading History for Santarus (NASDAQ:SNTS)

Santarus (NASDAQ SNTS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2013Gerald ProehlCEOSell56,643$31.95$1,809,743.8530,538View SEC Filing  
12/16/2013Kent SnyderDirectorSell7,500$31.95$239,625.00View SEC Filing  
12/9/2013Meules Julie DeVPSell15,165$31.95$484,521.75443View SEC Filing  
11/15/2013Kent SnyderDirectorSell7,500$32.01$240,075.00View SEC Filing  
11/11/2013Meules Julie DeVPSell15,165$31.94$484,370.10380View SEC Filing  
10/15/2013Gerald ProehlCEOSell50,000$22.32$1,116,000.0030,190View SEC Filing  
10/15/2013Kent SnyderDirectorSell7,500$22.31$167,325.00View SEC Filing  
10/10/2013Debra CrawfordCFOSell16,614$21.90$363,846.60166,326View SEC Filing  
10/9/2013Meules Julie DeVPSell15,165$21.14$320,588.10380View SEC Filing  
10/8/2013Maria Bedoya-ToroSVPSell10,000$21.39$213,900.0048,695View SEC Filing  
10/7/2013Carey FoxSVPSell17,100$21.91$374,661.0024,567View SEC Filing  
10/1/2013William C DenbyVPSell24,450$23.03$563,083.50View SEC Filing  
9/16/2013Gerald ProehlCEOSell50,000$22.19$1,109,500.0028,425View SEC Filing  
9/16/2013Kent SnyderDirectorSell7,500$22.18$166,350.00View SEC Filing  
9/10/2013Debra P CrawfordCFOSell19,000$22.38$425,220.00View SEC Filing  
9/9/2013Carey J FoxSVPSell17,100$22.19$379,449.00View SEC Filing  
9/9/2013Meules Julie A DeVPSell15,165$21.90$332,113.50View SEC Filing  
9/5/2013Michael D StepSVPSell30,303$23.17$702,120.51View SEC Filing  
9/3/2013William DenbyVPSell24,450$22.43$548,413.50View SEC Filing  
8/15/2013Kent SnyderDirectorSell7,500$25.89$194,175.00View SEC Filing  
8/12/2013Debra CrawfordCFOSell19,000$26.40$501,600.00166,326View SEC Filing  
8/9/2013Meules Julie DeVPSell15,165$26.55$402,630.75380View SEC Filing  
8/8/2013Maria Bedoya-ToroSVPSell10,000$27.35$273,500.0048,695View SEC Filing  
8/7/2013Carey FoxSVPSell17,100$27.36$467,856.0024,567View SEC Filing  
8/2/2013E David Ballard IISVPSell9,000$24.96$224,640.00View SEC Filing  
8/1/2013William C DenbyVPSell24,450$24.77$605,626.50View SEC Filing  
7/15/2013Kent SnyderDirectorSell35,000$25.36$887,600.00View SEC Filing  
7/10/2013Debra P CrawfordCFOSell19,000$23.17$440,230.00View SEC Filing  
7/9/2013Meules Julie A DeVPSell15,165$23.52$356,680.80View SEC Filing  
7/8/2013Maria E Bedoya-ToroSVPSell10,000$23.34$233,400.00View SEC Filing  
7/5/2013Michael D StepSVPSell30,301$21.76$659,349.76View SEC Filing  
7/3/2013Warren E HallVPSell28,749$21.54$619,253.46View SEC Filing  
7/2/2013E David Ballard IISVPSell9,000$21.45$193,050.00View SEC Filing  
7/1/2013William C DenbyVPSell25,050$21.56$540,078.00View SEC Filing  
6/10/2013Debra P CrawfordCFOSell19,000$21.45$407,550.00View SEC Filing  
6/10/2013Maria E Bedoya-ToroSVPSell10,000$21.57$215,700.00View SEC Filing  
6/10/2013Meules Julie A DeVPSell15,165$21.67$328,625.55View SEC Filing  
6/7/2013Carey J FoxSVPSell17,100$20.54$351,234.00View SEC Filing  
6/3/2013Daniel D BurgessDirectorSell8,000$21.34$170,720.00View SEC Filing  
6/3/2013E David Ballard IISVPSell9,000$21.34$192,060.00View SEC Filing  
6/3/2013William C DenbyVPSell24,450$21.46$524,697.00View SEC Filing  
5/15/2013Cha Alessandro DellaDirectorSell16,500$21.33$351,945.00View SEC Filing  
5/15/2013Technologies Ltd CosmoMajor ShareholderSell4,887,500$17.68$86,411,000.00View SEC Filing  
5/14/2013Michael E HermanDirectorSell25,000$20.77$519,250.00View SEC Filing  
5/10/2013Debra P CrawfordCFOSell18,643$19.27$359,250.61View SEC Filing  
5/9/2013Meules Julie A DeVPSell15,165$20.10$304,816.50View SEC Filing  
5/8/2013Maria E Bedoya-ToroSVPSell10,000$20.53$205,300.00View SEC Filing  
5/1/2013Daniel D BurgessDirectorSell8,000$17.88$143,040.00View SEC Filing  
5/1/2013William C DenbyVPSell24,450$17.90$437,655.00View SEC Filing  
4/10/2013Debra P CrawfordCFOSell19,000$16.82$319,580.00View SEC Filing  
12/18/2012Ted W LoveDirectorBuy185,000$10.88$2,012,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Santarus (NASDAQ SNTS) News Headlines

Santarus (SNTS) versus Shire (SHPG) Head to Head ContrastSantarus (SNTS) versus Shire (SHPG) Head to Head Contrast - March 6 at 11:34 AM
Head-To-Head Analysis: Santarus (SNTS) versus Emergent Biosolutions (EBS)Head-To-Head Analysis: Santarus (SNTS) versus Emergent Biosolutions (EBS) - September 24 at 10:20 AM

SEC Filings

Santarus (NASDAQ:SNTS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Santarus (NASDAQ:SNTS) Income Statement, Balance Sheet and Cash Flow Statement


Santarus (NASDAQ SNTS) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.